Charles Duncan
Stock Analyst at Cantor Fitzgerald
(4.10)
# 464
Out of 4,840 analysts
226
Total ratings
42.01%
Success rate
15.32%
Average return
Main Sectors:
Stocks Rated by Charles Duncan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Reiterates: Overweight | n/a | $4.36 | - | 6 | Mar 28, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Overweight | $28 | $21.98 | +27.39% | 21 | Feb 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | $140 → $150 | $108.07 | +38.80% | 6 | Feb 26, 2025 | |
| AXSM Axsome Therapeutics | Reiterates: Overweight | $153 | $105.07 | +45.62% | 22 | Feb 19, 2025 | |
| GHRS GH Research | Initiates: Overweight | $14 | $11.11 | +26.07% | 1 | Feb 13, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Overweight | n/a | $29.01 | - | 1 | Jan 10, 2025 | |
| BHVN Biohaven | Reiterates: Overweight | n/a | $15.64 | - | 17 | Dec 17, 2024 | |
| STOK Stoke Therapeutics | Reiterates: Overweight | n/a | $9.36 | - | 7 | Dec 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Overweight | $51 → $58 | $34.17 | +69.74% | 8 | Oct 30, 2024 | |
| ALKS Alkermes | Maintains: Overweight | $48 → $43 | $29.35 | +46.51% | 5 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $30.54 | - | 7 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.58 | - | 15 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $120.18 | +28.97% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $11.47 | - | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 | $13.42 | +160.80% | 6 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $4.33 | +200.23% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.47 | - | 6 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.30 | - | 2 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.30 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.06 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $24.49 | +38.83% | 9 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $52 → $50 | $29.75 | +68.07% | 3 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $5 | $2.81 | +77.94% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $0.46 | +763.00% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.59 | +151.57% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $58 | $29.75 | +94.96% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $110 | $1.03 | +10,579.61% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $80 | $2.37 | +3,275.53% | 5 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.10 | +172.73% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $11 | $7.53 | +46.08% | 2 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $12 | $7.89 | +52.09% | 2 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $146 → $168 | $7.25 | +2,217.24% | 6 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.14 | +834.58% | 1 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $18.54 | +978.75% | 3 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $0.29 | +1,302.03% | 3 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $2.11 | +1,037.44% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $372 → $144 | $1.97 | +7,209.64% | 6 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $1.45 | +175.86% | 2 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 → $39 | $54.54 | -28.49% | 4 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $15 | $78.69 | -80.94% | 4 | Feb 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $0.47 | - | 3 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $5.71 | +3,052.36% | 1 | Oct 9, 2017 |
COMPASS Pathways
Mar 28, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.36
Upside: -
ACADIA Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $28
Current: $21.98
Upside: +27.39%
Jazz Pharmaceuticals
Feb 26, 2025
Downgrades: Neutral
Price Target: $140 → $150
Current: $108.07
Upside: +38.80%
Axsome Therapeutics
Feb 19, 2025
Reiterates: Overweight
Price Target: $153
Current: $105.07
Upside: +45.62%
GH Research
Feb 13, 2025
Initiates: Overweight
Price Target: $14
Current: $11.11
Upside: +26.07%
Bright Minds Biosciences
Jan 10, 2025
Initiates: Overweight
Price Target: n/a
Current: $29.01
Upside: -
Biohaven
Dec 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.64
Upside: -
Stoke Therapeutics
Dec 10, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.36
Upside: -
Harmony Biosciences Holdings
Oct 30, 2024
Maintains: Overweight
Price Target: $51 → $58
Current: $34.17
Upside: +69.74%
Alkermes
Oct 25, 2024
Maintains: Overweight
Price Target: $48 → $43
Current: $29.35
Upside: +46.51%
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $30.54
Upside: -
Sep 30, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.58
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $155
Current: $120.18
Upside: +28.97%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.47
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $35
Current: $13.42
Upside: +160.80%
Aug 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $4.33
Upside: +200.23%
Jul 31, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.47
Upside: -
Jul 30, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.30
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.30
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.06
Upside: -
Mar 22, 2024
Reiterates: Overweight
Price Target: $34
Current: $24.49
Upside: +38.83%
Oct 24, 2023
Assumes: Overweight
Price Target: $52 → $50
Current: $29.75
Upside: +68.07%
Sep 22, 2023
Initiates: Overweight
Price Target: $5
Current: $2.81
Upside: +77.94%
Sep 7, 2023
Reiterates: Overweight
Price Target: $4
Current: $0.46
Upside: +763.00%
Aug 22, 2023
Reiterates: Overweight
Price Target: $4
Current: $1.59
Upside: +151.57%
Aug 22, 2023
Reiterates: Overweight
Price Target: $58
Current: $29.75
Upside: +94.96%
Aug 22, 2023
Reiterates: Overweight
Price Target: $110
Current: $1.03
Upside: +10,579.61%
Aug 16, 2023
Reiterates: Overweight
Price Target: $80
Current: $2.37
Upside: +3,275.53%
Aug 14, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.10
Upside: +172.73%
Dec 6, 2022
Downgrades: Neutral
Price Target: $16 → $11
Current: $7.53
Upside: +46.08%
Nov 22, 2022
Upgrades: Overweight
Price Target: $9 → $12
Current: $7.89
Upside: +52.09%
Jun 8, 2022
Maintains: Overweight
Price Target: $146 → $168
Current: $7.25
Upside: +2,217.24%
Feb 18, 2022
Initiates: Overweight
Price Target: $20
Current: $2.14
Upside: +834.58%
Feb 18, 2022
Initiates: Overweight
Price Target: $200
Current: $18.54
Upside: +978.75%
Apr 20, 2021
Downgrades: Neutral
Price Target: $8 → $4
Current: $0.29
Upside: +1,302.03%
Oct 23, 2020
Initiates: Overweight
Price Target: $24
Current: $2.11
Upside: +1,037.44%
Sep 28, 2020
Downgrades: Neutral
Price Target: $372 → $144
Current: $1.97
Upside: +7,209.64%
Jun 1, 2020
Maintains: Overweight
Price Target: $3 → $4
Current: $1.45
Upside: +175.86%
May 4, 2020
Reiterates: Overweight
Price Target: $35 → $39
Current: $54.54
Upside: -28.49%
Feb 21, 2020
Reiterates: Neutral
Price Target: $14 → $15
Current: $78.69
Upside: -80.94%
Nov 15, 2017
Upgrades: Overweight
Price Target: n/a
Current: $0.47
Upside: -
Oct 9, 2017
Initiates: Overweight
Price Target: $180
Current: $5.71
Upside: +3,052.36%